INmune Bio Inc
Veridion Score
Composite trend over time
Why is INMB moving today?
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INMB.
INMB insider activity
INmune Bio Inc
3 insiders bought in the last 90 days
Net buying: $40K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-02 | Juda Scott | Insider | sell | $0.13 | 14,801 | 14,802 | $2K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Juda Scott | Insider | buy | $1.40 | 14,801 | 86,404 | $21K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Lowdell Mark William | Insider | sell | $0.13 | 7,211 | 7,212 | $901 | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Lowdell Mark William | Insider | buy | $1.40 | 7,211 | 1,518,017 | $10K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Moss David J | Insider | sell | $0.13 | 9,014 | 9,014 | $1K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moINMB contract awards, year to date.
Public federal awards linked to this ticker.
INMB lobbying filings, year to date.
Registered lobbying filings matched to INmune Bio Inc.